HomeBUSINESS
BUSINESS

Astellas Delivers Positive Data in 1st HIF-PH Inhibitor Study in Japan
(Nov.1.2017)

Astellas Pharma on October 31 released topline data from the first Japan study completed for its hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor roxadustat, which showed its efficacy in anemia in chronic kidney disease (CKD) patients on peritoneal dialysis ...
(LOG IN FOR FULL STORY)

News Calendar